Gilead Sciences Inc. (GILD) launched its combination HIV treatment Atripla in July 2006 to bolster the company's already strong presence in treating the virus - 84% of Gilead's second-quarter product sales of $905 million came from HIV treatments.
The drug consists of Gilead's Truvada - in turn made with its Viread and Emtriva drugs - and Bristol-Myers Squibb Co.'s (BMY) Sustiva. It is the first once-daily single tablet regimen for HIV that can be used as stand-alone therapy or in combination with other antiretrovirals. Approval in the European Union and Canada is pending.
THE DRUG: Atripla is approved in the United Stated to treat adults with HIV-1 infection, the virus that causes AIDS. The drug can be combined with other HIV/ AIDS therapies and was approved in less than three months as part of an agency program to more quickly bring life-saving medicines to the market. The most common adverse events include headache, dizziness, abdominal pain, nausea, vomiting and rash.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment